ACP: DOAC Dos and Don'ts Primer with Stephan Moll, MD

ACP 2021: Dr Stephan Moll covers the basics of DOAC duration for VTE, use of anticoagulation in special populations, and perioperative use of DOACs

How do you gauge a patient's "DOAC Hate Factor" and why is it important?

In his presentation "DOAC Dos and Don'ts" at the American College of Physicians Internal Medicine Meeting 2021: Virtual Experience, Stephan Moll, MD, spoke first about dosing and duration of treatment for venous thromoboembolism (VTE) using the "new" direct oral anticoagulants (DOACs) and then reviewed the approach to anticoagulant therapy in a range of special populations, including patients with obesity, with cancer, and renal compromise. He finishes his talk with a quick review of the evidence on perioperative anticoagulation.

Quantifying the "DOAC Hate Factor," he explains, is important when discussing continuation or discontinuation of anticoagulation therapy because patient preference has to be considered here. Once you know, on a scale from 0 to 10, how much hate there is, you can ask questions and try to accommodate where it's possible.

The slide show that follows is based on Dr Moll's presentation and includes links to many of the studies he mentions.

Stephan Moll, MD is Professor of Medicine in the Department of Medicine, Division of Hematology, at the University of North Carolina School of Medicine, in Chapel Hill, NC.